---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-073326"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T20:15:52.397205+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaccitech reports positive final Phase 1b/2 HBV002 data; two patients achieve non-detectable HBsAg

## Summary
- Two of five patients with baseline HBsAg <100 IU/mL in Group 3 developed non-detectable HBsAg, sustained eight months after last dose.
- Group 3 mean HBsAg reduction 0.76 log10 at 2 months (p<0.001) and 0.98 log10 at 8 months (p<0.001).
- VTP-300 monotherapy in Group 2 showed 0.7-1.4 log10 declines in three participants; robust T cell response correlated with HBsAg decline.
- Phase 2b trial HBV003 >40% enrolled (48/120); interim data expected Q4 2023.
- Phase 2a trial with Arbutus (VTP-300 after AB-729) in 40 patients; interim data expected Q4 2023.

## SEC filing metadata
- accession: 0001104659-23-073326
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465923073326/0001104659-23-073326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465923073326/tm2319306d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-073326
- JSON: https://secwatch.observer/filing/0001104659-23-073326.json
- Plain text: https://secwatch.observer/filing/0001104659-23-073326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.